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ABSTRACT
The p53 transcription factor plays an important role
in genome integrity. To perform this task, p53 reg-
ulates the transcription of genes promoting various
cellular outcomes including cell cycle arrest, apop-
tosis or senescence. The precise regulation of this
activity remains elusive as numerous mechanisms,
e.g. posttranslational modifications of p53 and (non-
)covalent p53 binding partners, influence the p53
transcriptional program. We developed a novel,
non-invasive tool to manipulate endogenous p53.
Nanobodies (Nb), raised against the DNA-binding do-
main of p53, allow us to distinctively target both wild
type and mutant p53 with great specificity. Nb3 pref-
erentially binds ‘structural’ mutant p53, i.e. R175H
and R282W, while a second but distinct nanobody,
Nb139, binds both mutant and wild type p53. The
co-crystal structure of the p53 DNA-binding domain
in complex with Nb139 (1.9 A˚ resolution) reveals
that Nb139 binds opposite the DNA-binding sur-
face. Furthermore, we demonstrate that Nb139 does
not disturb the functional architecture of the p53
DNA-binding domain using conformation-specific
p53 antibody immunoprecipitations, glutaraldehyde
crosslinking assays and chromatin immunoprecipi-
tation. Functionally, the binding of Nb139 to p53 al-
lows us to perturb the transactivation of p53 target
genes. We propose that reduced recruitment of tran-
scriptional co-activators or modulation of selected
post-transcriptional modifications account for these
observations.
INTRODUCTION
The p53 protein is of great importance in cancer biology as
it mediates innate tumor suppression. This is underscored
by its high mutation frequency in human cancers, presence
as a germ-line mutation in Li–Fraumeni cancer prone fam-
ilies and highly penetrant cancer predisposition in p53 null
mice. Its role as a barrier to tumor development is only
one of many as it is centered within numerous signalling
pathways. As such, p53 has been widely considered as the
master regulator of cell fate in unstressed conditions, where
it is held at a basal level by its negative regulator, Mdm2,
an E3 ubiquitin ligase, which binds to p53 and targets it
for proteasomal degradation. When challenged with vari-
ous stress conditions, however, this inhibition eases and p53
target genes are transactivated. p53-responsive genes have
been documented to be involved in among others cell cycle
arrest, apoptosis and senescence (1,2).
Active p53 consists of a tetramer made up of four iden-
tical subunits. Each monomer, in turn, retains an architec-
ture commonly found in transcriptional regulators: an N-
terminal transactivation domain (residues 1–60), a proline-
rich region (residues 63–97), an evolutionarily conserved
core DNA-binding domain (DBD) (residues 100–300), a
linker region (residues 301–323), a tetramerisation domain
(residues 324–355) and finally, a C-terminal regulatory do-
main (residues 360–393) (3).
p53 is inactivated in over half of all human cancers, either
throughTP53mutations or through alterations in genes en-
coding up- and downstream regulators of p53. In the former
case, over 80% of cancer-derived p53 mutations are found
within the DBD (4). This clearly illustrates the importance
of the DBD. To date more than 125 protein-coding genes
have been documented to be direct transcriptional targets
of p53 (5). Aside from being a transcriptional co-activator,
p53 is also known for transcriptional repression (6). In ad-
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dition, it has even been demonstrated that p53 can exercise
its influence through a transcription-independent apoptotic
response (7).
Multiple mechanisms within the cell are in play to
fine-tune the p53 transcriptional program. These include
posttranslational modifications of p53, covalent and non-
covalent p53 binding partners and p53 response elements
of variable binding affinity. Each of these features dynam-
ically adds to the combinatorial regulation of the p53 re-
sponse, and this magnitude of variables has made under-
standing the p53 transactivation requirements a formidable
task (1,8). A prerequisite therefore is that potent research
tools are available. As such, p53 over-expression and knock-
out mutations among others have been repeatedly applied
to great effect. However, investigating p53 at an endogenous
level in a non-invasive manner still remains tasking.
Here, we produced versatile and functional monoclonal
single chain antibodies against the p53 DBD based on
camelid heavy-chain-only antibodies. These single chain an-
tibodies, also known as nanobodies, represent the small-
est (15 kDa), intact, native antigen-binding fragment (9).
Their specific biophysical and biochemical properties and
their potential of targeting novel epitopes render them a
potent research tool in diverse fields, e.g. oncology (10–13),
parasitology (14,15), neuropathology (16) and immunology
(17).
These nanobodies were applied with great effect within
the cell as intrabodies and proved to be an effective research
tool to manipulate the p53 transcriptional program. We
show that a nanobody is able to disrupt the p53 transcrip-
tional program without altering endogenous p53 levels in a
radical fashion.
MATERIALS AND METHODS
Reagents and antibodies
Anti-V5 was purchased from Invitrogen (Merelbeke, Bel-
gium). Anti-p53 (DO1), etoposide, nutlin-3a, RNase A,
proteinase K and glutaraldehyde were purchased from
Sigma-Aldrich (Diegem, Belgium). Anti-HA was pur-
chased from Roche Applied Science (Vilvoorde, Belgium).
Anti-p63 (BC4A4) was purchased from Abcam (Cam-
bridge, UK). Anti-p73 (E4) and anti-NTF2 were purchased
from Santa Cruz Biotechnology (Heidelberg, Germany).
Anti-actin (C4) was purchased from MP Biomedicals (Il-
lkirch, France).
Generation of nanobodies
p53 nanobodies, raised against the p53 DBD (residues
92–312), were obtained in collaboration with the VIB
Nanobody Service Facility. The immunization and pan-
ning procedures, essential for obtaining the p53 nanobod-
ies, were performed as previously described (18). Recom-
binant V5-tagged nanobodies were generated for immuno-
precipitation experiments. The V5-tag allows retrieval of
nanobodies using anti-V5 antibody coupled to agarose.
Cloning, expression and purification of recombinant V5-
tagged nanobodies were performed as previously described
(18). The nanobodies were also re-cloned in a modified
pcDNA3.1 His6 vector (Invitrogen) or in the pLVTX Tight
Puro vector (Clontech, Saint-Germain-En-Laye, France)
for transient intracellular expression or generation of sta-
bly expressing cell lines, respectively (see below).
Generation of recombinant untagged p53 DBD
The p53 DBD (residues 92–312) was purified as previ-
ously described (19). Briefly, the cDNA fragment was sub-
cloned in the pTYB12 vector (NEB, Evry, France). An ini-
tial affinity purification, using chitin resin (NEB), was per-
formed according to the manufacturers’ instructions. The
purified protein was successively processed via a Superdex
75 (16/60) (GE Healthcare) (150 mM NaCl, 50 mM Tris,
5 mM DTT, pH 8.0) and a HiTrap Heparin column (GE
Healthcare) (50 mM NaCl, 20 mM Tris, 5 mM DTT, pH
8.0). The final concentration was determined using a spec-
trophotometric approach. The p53 DBD was finally dia-
lyzed against 50 mM Tris, 150 mM NaCl, 5 mM DTT, pH
8.0 and stored at −20◦C.
Cell culture and transfection
U2OS, U2OS pGL13 and HEK293T cell lines were cul-
tured at 37◦C, 10% CO2 in DMEM (Gibco Life Technolo-
gies, Gent, Belgium) supplemented with 10% FBS. Tran-
sient transfections were executed with Jetprime (Polyplus
Transfections, Illkirch, France) and performed according to
the manufacturers’ instructions.
Generation of stable U2OS cell lines
U2OS cells stably expressing V5-tagged p53 DBD Nbs
or GFP Nb were developed using the Lenti-XTM Tet-
OnR Advanced Inducible Expression System from Clon-
tech as previously described (13). Briefly, 250 × 103 cells
were seeded in a six-well plate, after which viral mixture
(nanobody and regulator) (MOI: 10) was added in a total
amount of 2ml. Cells were then centrifuged for 1 h at 1200 g,
after which a two-week selection procedure with neomycin
(0.4 mg/ml) and puromycin (1g/ml) followed. Expression
of nanobodies was induced by the addition of 500 ng/ml
doxycycline for 24–48 h.
Immunoprecipitation and immunoblotting
U2OS and/or HEK293T cells were treated with ice-cold ly-
sis buffer (PBS, 0.5% NP-40, 1 mM PMSF and a protease
inhibitor cocktail mix) and the extract was centrifuged for
10 min at 20 × 103 g at 4◦C. Concentration of the cyto-
plasmic extract was determined using a Bio-Rad protein
assay (Bio-Rad Laboratories, Nazareth Eke, Belgium) ac-
cording to the manufacturers’ prescriptions. Subsequently
0.5 mg of cytoplasmic extract was incubated with 2–5 g
recombinant V5-tagged nanobody or 2–5 g lgG antibody
of interest for 1–2 h at 4◦C. The former step was skipped
when working with stable nanobody-expressing U2OS cell
lines. Afterward, 15 l anti-V5 agarose (Sigma) or prote-
inG sepharose (GE Healthcare) was added to the sample
and incubated for 1–2 h at 4◦C. The beads were washed
with lysis buffer, boiled for 5 min in Laemmli sample buffer
and proteins were fractionated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Western
blotting was performed as previously described (20).
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Isothermal titration calorimetry
The binding affinity of p53 DBD to p53 DBD Nb139 was
measured at 30◦C by isothermal titration calorimetry (ITC)
using a Microcal VP-ITC as previously described (18). Un-
tagged p53 DBD and V5-tagged p53 Nb139 were dialyzed
against 20mMTris, 150mMNaCl, pH 7.5. The precise pro-
tein concentrations used for the ITC are described in Sup-
plementary Figure S1. ITC data was fitted using a ‘One Set
of Sites’ model.
Luciferase assay
A luciferase assay was performed as previously described
(21). Briefly, 180 × 103 U2OS cells in which the pGL13 lu-
ciferase reporter is stably integrated were plated on 12-well
plates 1 day before transfection. A nanobody and a beta-
galactosidase vector were co-transfected (see above). At 24
h post-transfection, the cells were reseeded in a 96-well plate
and treated with or without nutlin-3a (5 M). The next
day, luciferase activity from triplicate samples was mea-
sured by chemiluminescence with a Topcount luminometer
(Canberra-Packard). The level of firefly luciferase activity
was normalized by that of the beta-galactosidase activity in
each experiment.
Real-time quantitative PCR
Total RNAwas isolated from a stable nanobody-expressing
U2OS cell line using a High Pure RNA Isolation Kit
(Roche) according to the manufacturers’ preferences.
RNA quality was assessed for each sample by determin-
ing the 260/280 ratio using a spectrophotometer (Nan-
odrop, Wilmington, DE, USA). Complementary DNA
(cDNA) was immediately synthesized using a Transcriptor
First Strand cDNA Synthesis Kit with oligo(dT) primers
(Roche). The cDNA concentration was determined using
a spectrophotometer. Samples were stored afterward at
−80◦C.
Primers for PUMA, GADD45a and the reference genes
(ACTB, B2M, GADPH, G6PDH, PGK1 and cyclophilin)
were in-house validated. All primer efficiencies lie within
the range of 90–110%. The sequence of the primers can be
found in Supplementary Table S1. Primers for p21 (#631)
andMDM2 (#3499) were derived from RTPrimerDB (22).
RTqPCR was performed using a LightCycler 480 (96-
plate platform) (Roche). Each reaction consisted of 6 l of
cDNA (1/12 dilution) mixed with 0.75 l of a 10 M solu-
tion of each primer and 7.5 l of 2× LC480 SYBR Green
Master (Roche). The PCR conditions were as follows: 10
min at 95◦C, followed by 45 cycles of denaturation (10 s at
95◦C), and elongation (45 s at 60◦C). All reactions were per-
formed in triplicate and no template controls were included
for all genes.
Stability analysis of the different references was per-
formed using the geNormPLUS application in the qbase-
PLUS software version 2.0 (Biogazelle, Zwijnaarde, Bel-
gium) (23).
Crystallization and structure determination
Nb139 and p53DBD, both dialyzed against 50 mM NaCl,
50 mMTris, 5 mMDTT, pH 7.2, were mixed at a 1.2:1 ratio
to a final concentration of 6.56 mg/ml, before adding the
freshly formed complex to the crystallization set-up. After
screening with commercially available crystallization kits,
crystals of the complex were obtained at 20◦C using the
hanging-drop vapor diffusion method (24) after mixing 1
l protein solution with 1 l reservoir solution equilibrated
against 125l 0.2Mpotassium formate 20%w/v PEG3350
reservoir solution (Molecular Dimensions JCSG+ condi-
tion 1.10). The crystals were cryoprotected by transfer to
a solution consisting of 0.2 M potassium formate 20% w/v
PEG 3350 and 20% glycerol and subsequently vitrified in
liquid nitrogen. Data was collected at 100 K on the Prox-
ima1 beamline of the SOLEIL synchrotron on a 6M Pila-
tus detector (Gif-Sur-Yvette, France). One Nb139/p53 core
domain co-crystal diffracted to 1.9 A˚ resolution and a full
data-set was collected. The crystal belongs to space group
P212121 with unit-cell dimensions a = 46.4 A˚, b = 68.3 A˚
and c = 110.0 A˚.
Data was processed with the software package XDS
(25) and the unit-cell content was estimated with the pro-
gram MATTHEW COEF from the CCP4 program suite
(26). A molecular replacement approach was applied with
PHASER-MR (27) using a search model with the coor-
dinates of the a nanobody against Escherichia coli MazE
(PDB entry 1MVF). Prior to the search all three com-
plementarity determining regions were deleted. Using the
molecular replacement solution, ARP/wARP (28) rebuilt
the correctmodel to almost completion. The refinementwas
completed by combining manual building using Coot (29)
and automated maximum likelihood refinement as imple-
mented in phenix.refine (30). Structure quality was checked
using the MolProbity (31). Full data collection and refine-
ment statistics are reported in Supplementary Table S2. The
extreme 21 C-terminal p53DBD residues were missing and
were thus not included in subsequent analysis. Surface ac-
cessibility was determined with Nacces 2.1.1 using a probe
with a radius 1.4 A˚ (32), and residues involved in hydrogen
bond formation and van der Waals interactions were deter-
mined by HBPLUS v.3.06 (33) and as residues harboring
non-hydrogen atoms in their environment closer than 4 A˚,
respectively. These data are reported in Supplementary Ta-
ble S3.
Crosslinking assay
HEK293T cells were transiently transfected with indicated
nanobody plasmids and lysed with lysis buffer (0.5% NP-
40, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 mM NaF,
1 mM NaVO3, 1 mM DTT, 1 mM PMSF and protease in-
hibitormixture) 36 h after transfection.Glutaraldehydewas
added to the lysate at indicated concentrations. After incu-
bating the lysate on ice for 20 min, the glutaraldehyde reac-
tions were stopped by adding Laemmli sample buffer, and
the samples were heated at 100◦C for 5 min and resolved
by SDS-PAGE. Western blot analysis was performed with
anti-p53 antibody (DO1).
Chromatin immunoprecipitation
A chromatin immunoprecipitation (ChIP) assay was per-
formed as previously described (34). Briefly, lysates from
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Figure 1. Characterization of p53 DBD Nanobodies. (a) Recombinant V5-tagged Nb3, Nb139 or GFP Nb (2 g) were added to wild type p53-bearing
U2OS and HEK293T cell lysates (500 g). Nanobody–protein complexes were immunoprecipitated and analysed for the interaction with p53 protein
family members. Nb139 is only able to interact with wild type p53, leaving p63 and p73 unaffected. (b) Recombinant V5-tagged nanobodies (2 g) were
added to HEK293T cell lysates (500 g), in which HA-tagged hot spot p53 mutants, i.e. R175H, R273H and R282W, were expressed at variable levels (see
input). A co-immunoprecipitation was performed relying on the V5-tagged nanobodies. The mutual interaction between mutant p53 and nanobody was
subsequently analysed via western blot. Nb3 has a preference for ‘structural’ mutant p53, i.e. R175H and R282W, while Nb139 binds p53 irrespective of
the mutation. The binding characteristics of Nb3 and Nb139 are compared to that of the control GFP Nb.
stable nanobody-expressing U2OS cell lines were sonicated
with a Bioruptor Sonication SystemUCD-300 (Diagenode,
Seraign, Belgium) 21 times for 30 s with intermittent cool-
ing. Anti-p53 (DO1) was used to perform the precipitation
of the DNA-bound p53, whereas anti-NTF2 was used as an
aspecific control. The chromatin-antibody protein complex
was eluted from the protein-G-Sepharose beads with freshly
prepared elution buffer (0.1MNaHCO3 and 1% SDS). Re-
verse crosslinking and RNase treatment of the ChIP eluate
were simultaneously performed overnight at 65◦C.The sam-
ples were digested with proteinase K for 3 h at 50◦C. The
DNAwas finally purified usingQIAquick PCRPurification
Kit (Qiagen, Venlo, TheNetherlands). The elutedDNAwas
subsequently submitted to a RTqPCR (see above). The se-
quences of the primers used can be found in Supplementary
Table S4 (35).
RESULTS
Nanobody 3 and nanobody 139 target the p53 DBD
We developed two single domain antibodies against the
DBD of p53, termed Nb3 and Nb139 (see Materials
and Methods). Their binding specificity was determined
by investigating the cross-reactivity with members of the
p53 protein family, i.e. p53, p63 and p73. The p53 fam-
ily members retain a similar basic modular structure.
However, despite a rather limited overall homology, they
display 60% similarity within the DBD (36). By using
a co-immunoprecipitation set-up we incubated recombi-
nant Nb3, Nb139 or a control GFP Nb (37) with either
HEK293T or U2OS cell lysates. In both cases, Nb139 was
able to bind endogenous wild type p53 but did not inter-
act with p63 nor with p73 (Figure 1a). Nb3 on the other
hand failed to show a significant interaction with wild type
p53 or with the other p53 protein family members. Interest-
ingly, in over-expression experiments using HA-tagged hot
spot p53mutants, we observed thatNb3 preferentially inter-
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Figure 2. Establishment of Nb139’s inhibitory effect on the p53 transcrip-
tional program. The relative luciferase activity wasmeasured inU2OS cells
stably harboring a luciferase gene. This cell line was transiently transfected
with (w) or without (wo) Nb3, Nb139 or GFP Nb, and treated 24 h post-
transfection with nutlin-3a (5 M) for an additional 24 h. The luciferase
activity was then finally measured. Nb139 causes a significant reduction
in luciferase transcription in comparison to the control GFP Nb. An un-
paired student t-test was performed (*** < 0.001).
acted with ‘structural’ mutant p53, i.e. R175H and R282W
(Figure 1b), in comparison to the control GFP Nb. Nb139,
on the other hand, interacted with p53, regardless of mu-
tations in the DBD. These ‘structural’ mutants are known
to destabilize the overall architecture of the DNA-binding
surface, rendering the p53 protein inactive (3). As a result,
it was not opportune to evaluate the effect of Nb3 on the
transcriptional characteristics of wild type p53, in contrast
to Nb139. Nb3 was therefore included, in addition to the
GFP Nb, as a control in subsequent experiments.
The KD of Nb139 determined by ITC is ∼1 M (Sup-
plementary Figure S1a and b). This rather weak KD indi-
cates that the interaction between the p53DBD and Nb139
is of a transient nature. However, depending on the molec-
ular environment, volatile protein–protein interactions are
known to change their characteristics and obtain a more
permanent binding pattern (38,39). The binding affinity
value is thus merely to be considered indicative for a cellular
context. In addition, the binding stoichiometry with which
Nb139 interacts with the p53DBD was determined at 1:1.
Thus, since Nb139 conformed to the needs for a precise re-
search tool, i.e. specificity and affinity, we set out to investi-
gate the influence of Nb139 on the transcriptional program
of wild type p53.
Nb139 perturbs the p53 transcriptional program in a non-
specific fashion
With Nb139 specifically targeting the wild type p53DBD,
we assessed how it would alter the transcriptional functions
attributed to this domain. Therefore, we performed a trans-
activation assay by transiently transfecting Nb3, Nb139 or
the control GFP Nb in U2OS cells stably harboring a lu-
ciferase reporter gene. The luciferase cDNA is preceded by
13 repeats of a p53 consensus response element. We found
that Nb139 is able to significantly diminish luciferase ex-
pression in comparison to the control condition (Figure 2).
Thus, it became apparent that Nb139 can influence the p53
transcriptional program. We took this one step further by
looking into the regulation of p53 target genes.
To succeed in this endeavor we developed U2OS cell
lines with doycycline-inducible nanobody expression. This
not only guarantees a homogenous nanobody expression
throughout the cell population but also allows us to tune
nanobody expression (Figure 3a). p53 isoform specificity is
corroborated in these cell lines (Supplementary Figure S2).
Next, we performed a RTqPCR, establishing that Nb139
suppresses p53’s transcriptional program. The mRNA lev-
els of p53 target genes involved in cell cycle arrest (i.e. p21,
GADD45A), apoptosis (i.e. PUMA) and p53 regulation (i.e.
MDM2) all decreased in a significant manner in the pres-
ence of Nb139 (Figure 3b). Hence, this nanobody impacts
transcription-dependent functions of p53 in a non-specific
fashion.
The structural evidence advocates a rupture of the functional
architecture of p53
To understand at the molecular level how Nb139 quenches
the p53 transcriptional program, we determined the co-
crystal structure of the p53DBD in complex with Nb139.
The structure was obtained at a resolution of 1.9 A˚
and reveals that Nb139 binds the immunoglobulin-like -
sandwich fold of theDBDon the opposite side of theDNA-
binding surface (Figure 4a). While four other crystal pack-
ing contacts between Nb139 and the p53DBD could be
identified, none of them made extensive protein–protein in-
teractions through the complementary determining regions
(CDRs) of the nanobody (Supplementary Table S3). The
DBD consists of a hydrophobic core formed by the stack-
ing of two twisted antiparallel -sheets. This inner core is
flanked by the DNA interaction surface, which involves two
loops stabilized by a zinc ion, and a loop-sheet-helix motif.
On the opposite side of the DBD, the three CDRs of Nb139
enclose the leucine-rich loop connecting -strand 9 and -
strand 10, thereby anchoring CDR2 into the core of the -
sandwich through the formation of hydrogen bonds and van
der Waals interactions (Figure 4a and Supplementary Ta-
ble S3). The backbone of residues Gly104 and Pro101 of
CDR3 form hydrogen bonds with the side chains of Ser261
and Asn263 respectively while residues Thr32 of CDR1 and
Trp54 of CDR2 form backbone–backbone hydrogen bonds
with Gly262 and Leu264 of the p53 core domain (Figure
4b).
We performed a backbone superposition of 194 atoms
(Ser96 to Leu264) of the DBD from the Nb139/DBD com-
plex with four molecules of the asymmetric unit from the
previously determined free human DBD (PDB entry 2OCJ
(40)). This resulted in RMSDS of 0.54, 0.53, 0.51 and
0.67 A˚ respectively. Overall, the structure distinctively il-
lustrated that Nb139 does not disturb the architecture of
the DBD. To corroborate this finding, we performed a co-
immunoprecipitation using conformation-specific p53 anti-
bodies Ab1620 (wild type) and Ab240 (mutant) (Figure 4c)
(41). To this end, recombinant Nb3, Nb139 or the control
GFP Nb were incubated with either HEK293T or U2OS
cell lysates, after which the conformation-specific antibod-
ies were added in order to bind either wild type or mutant
p53. In the presence of Nb139, Ab1620 was still able to in-
teract with p53 suggesting that p53’s functional architec-
ture remains intact. However, the co-immunoprecipitation
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Figure 3. Nb139 reduces transcription of various p53 target genes. (a) Inducible expression of V5-tagged nanobodies in U2OS cells was verified in the
absence (−DOX) or presence (+DOX) of 500 ng/ml doxycycline (50 g crude lysate was loaded). (b) U2OS cell lines were consecutively treated with
doxycycline (500 ng/ml) (24 h) and etoposide (20 M) (24 h), after which the transcription levels of p53 target genes (p21,MDM2,GADD45a and PUMA)
were evaluated via RTqPCR. Irrespective of the target gene, Nb139 is able to significantly reduce mRNA levels in comparison to control conditions. A
paired student t-test was performed (** < 0.01 and *** < 0.001).
experiment also revealed that, in comparison to the other
conditions, Nb139 is only slightly more present in the p53-
Ab1620 complex. Thus, Nb139 could possibly not ade-
quately bind p53 in the presence ofAb1620. In addition,mi-
nor structural variations are present at the interaction inter-
face as the turn between -strand 9 and -strand 10 is dis-
placed away from the inner core of the p53-sandwich upon
binding of Nb139 (Figure 4d). As follows, we are strongly
inclined to conclude that Nb139 leaves the DBD’s architec-
ture unaffected, but additional experimentation is needed
to confirm this with absolute certainty.
Recently, the structure of a tetrameric DBD bound to the
full consensus site was solved, revealing a co-operative self-
assembling process for oligomerization (PDB entry 3KMD
(42)). First, two DBD monomers (A and B) form a p53
dimer across one half site of the DNAbymaking distinctive
protein–protein and protein–DNA interactions (Figure 5).
Subsequently, identical dimers can bind the dimeric com-
plex. In this configuration, each DBD monomer is stabi-
lized through protein–protein interactions at the dimer and
dimer–dimer interface as well as through protein–DNA in-
teractions, resulting in a stable tetrameric complex. This
oligomerization process is mediated through essential con-
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Figure 4. Structure of the Nb139/DBD complex. (a) Nb139 (green) with CDR1 (magenta), CDR2 (orange) and CDR3 (yellow) represented in cartoon,
bound to p53 core domain (blue) represented in cartoon/surface. The zinc ion of the DNA-binding interface is represented as a red sphere. (b) The
interaction between Nb139 and the DBD is established by hydrogen bounds (dashed lines) between the backbone and side chains of CDR1, CDR2 and
CDR3 with the leucine-rich loop connecting the -strand 9 and -strand 10 of the p53 core domain. (c) U2OS or HEK293T cell lysate (500 g) were
successively incubated with recombinant V5-tagged Nb3, Nb139 or GFP Nb (2 g) and 5 g of p53 conformation-specific antibodies, i.e. Ab1620 (wild
type) or Ab240 (mutant). Nanobody-p53 complexes were immunoprecipitated (relying on the used conformation-specific antibodies) and analysed for the
presence of p53. Nb139, nor other nanobodies, influences the architecture of p53. In addition, the presence of p53-bound nanobody was also evaluated
via western blot. (d) Backbone superposition of the p53DBD of the Nb139/DBD (blue) and four molecules of the asymmetric unit of 2OCJ (red, orange,
yellow and pink). Upon binding of Nb139, the loop connecting -strand 9 and -strand 10 is displaced away from the inner core of the -sandwich fold
(arrow).
formational changes in the backbone and side chains of
residues of the DBD at the dimer–dimer interface, result-
ing in tight surface complementarity (42).
Although the p53 dimer on its own is symmetrical
(in regard to the position of Nb139), formation of the
dimer–dimer complex breaks the symmetry. The result is
two unique binding sites for Nb139 when encountering a
tetrameric complex. The first one is located on the outer
side of the B and D core domain (Figure 5, green Nb139)
while the second one is located at the dimer–dimer inter-
face (Figure 5, orange Nb139). In the latter possibility, the
positively charged side chain of Arg28 of Nb139 would co-
incide with side chains of Val225 and Lys101 at the patch
II thereby breaking the dimer–dimer interface. Unfortu-
nately, electron density for Arg28 of CDR1 was lacking in
the Nb139/p53DBD domain complex, indicating disorder,
and could not be represented on the superposition. How-
ever, this superposition suggests that Nb139 might prevent
the formation of the tetrameric complex but not the p53
core domain dimer.
Nb139 permits endogenous p53 to bind p53-responsive pro-
moters
To validate the hypothesis that Nb139 interferes with
tetramer formation, we performed a crosslinking assay by
treating transiently nanobody-transfected HEK293T cells
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Figure 5. Superposition of Nb139 onto the tetrameric DBD in complex with its consensus site. Top and side views of the superposition of Nb139 onto
the p53 dimer (AB, blue)–dimer (CD, pink) of 3KMD reveals two possible binding sites. The green Nb139 is positioned outward on the tetramer while the
orange Nb139 is positioned at the side of the dimer–dimer interface. Binding at patch II of the dimer–dimer interface induces conformational changes in
loop 7–8 away from the p53 DBD monomer position (green). Binding of Nb139 might prevent tetramerization by disrupting the formation of patch II
with Arg28 of CDR1. Electron density of the Arg28 side chain was lacking, indicating disorder.
with increasing amounts of glutaraldehyde. This set-up
demonstrated elegantly that Nb139 still allows the forma-
tion of p53 di- and tetramers (Figure 6a), both of which
form the basis for p53’s functional transcriptional charac-
teristics. As to see if this also meant that p53 is still able to
functionally bind its response elements in vivo, we executed
a ChIP assay by using a commercial p53 antibody (DO1)
to precipitate a p53/chromatin-complex. Hereby, we found
strong indications that Nb139 preserves the DNA-binding
characteristics of p53, with p53 binding the response ele-
ments of p21 andMDM2 (Figure 6b). Thus, another tran-
scriptional inhibitory mechanism, e.g. the reduced recruit-
ment of transcriptional co-activators, must be at play as
Nb139 is able to modulate the p53 transcriptional program
while leaving the p53 conformation unaffected.
DISCUSSION
The p53 protein is indisputably an important tumor sup-
pressor and is often referred to as ‘the guardian of the
genome’ (43). In unstressed conditions p53 is held at basal
levels, while a wide variety of intra- and extracellular
stress signals promote p53 stabilization and activation. As
such, p53 is able to provide an appropriate transcription-
dependent and -independent response, contributing to di-
verse biological functions, e.g. cell cycle arrest, apoptosis,
angiogenesis, energy metabolism, motility and migration
(44). We are at the beginning of understanding many of
these functions and the mechanism by which p53 is regu-
lated. It is clear, for example, that p53 transcriptionally reg-
ulates the expression of different genes. The p53 transcrip-
tional program is fine-tuned by many mechanisms, which
enable p53 to differentiate between the vast repertoire of tar-
get genes (8,45). Among others, post-translational modifi-
cations of p53, (non)covalent p53 binding partners and p53
response elements of variable binding affinity. However, de-
spite intensive effort, this area of study still remains elusive.
Technological innovations have always proven to advance
the knowledge of p53. The development of p53 genotype-
specific knock-in/outmice (46), conformation-specific anti-
bodies (41), p53-null cell lines (47), p53-specific siRNA (48),
MDM2 inhibitors (49) and many more have all contributed
12936 Nucleic Acids Research, 2014, Vol. 42, No. 20
Figure 6. Nb139 maintains wild type conformation of p53. (a) The p53 monomers, derived from transiently nanobody-transfected HEK293T lysates, were
crosslinked with an increasing amount of glutaraldehyde (0: 0%, 1: 0.001% and 2: 0.01%). All three nanobody conditions allow p53 to form dimers and
tetramers. Arrows indicate mono-, di- and tetramer conformation of p53. (b) The U2OS cell lines were consecutively treated with doxycycline (500 ng/ml)
(24 h) and etoposide (20 M) (24 h), after which the ChIP was performed. In the presence of Nb139 p53 is able to bind in vivo the response elements of
p21 (primer set F) andMDM2 (primer set E). After taking the background signal (i.e. signal derived from the input and anti-NTF2 antibody control) into
account, Nb139 differs in a similar significant fashion as GFP Nb from the reference TBP gene. A paired student t-test was performed (* < 0.05). In the
absence of Nb3, p53 binds to p21 and MDM2, but not in a significant manner with P-values of respectively 0.059 and 0.063.
pieces to the ever-growing complex p53 puzzle. However,
past studies have revealed a disparity between several hy-
potheses generated by in vitro transfection studies and in
vivomouse models, which is probably explained by the abil-
ity of mouse models to preserve crucial stoichiometric re-
lationships between p53 and its negative and positive reg-
ulators (50). Nevertheless, in vitro studies will remain in-
dispensable as they provide a cost/time-effective, important
source of scientific data, that in turn can be validated in vivo.
Taking both of these concerns into consideration, we
have applied nanobody technology to the field of p53. We
have developed research tools, Nb3 andNb139, which allow
us to specifically target endogenous p53 in a non-invasive
manner. Nb3 binds ‘structural’ mutant p53. Despite us not
having investigated its full potential, Nb3 may be of invalu-
able importance in the field of re-activating loss-of-function
p53 (51,52). Liu et al. recently proposed certain criteria to
screen for genuine p53 re-activation (53). With Nb3 already
complying with one of these criteria, i.e. the specific binding
of ‘structural’ mutant p53, Nb3 is potentially considered a
valid candidate. If further research confirms that Nb3 re-
vives mutant p53, this nanobody could accelerate the ratio-
nal design of small molecules capable of stabilizing mutant
p53. As small molecule drug design is supported by struc-
tural biology, the co-crystal structure of Nb3 in complex
with the DBD could help identify the crucial binding site
or help generate hypotheses for structure-based design for
new p53 re-activating compounds (54).
Nb139, on the other hand, targets both mutant and wild
type p53. Specifically focusing on wild type p53, we demon-
strate that Nb139 is able to inhibit the transcriptional ca-
pabilities of p53 with surgical precision, as it maintains the
functional architecture and the DNA-binding characteris-
tics of p53. However, as to exclude possible ambiguousness,
regarding Nb139’s traits, additional experimentation can
be of interest. Assays such as circular dichroism, an elec-
trophoretic mobility shift assay or a Nb-based ChIP assay,
could unequivocally corroborate our findings that point to-
ward the conservation of the functional architecture of p53
in the presence of Nb139.
Other existing research tools fail to specifically target sin-
gle functions of p53. For example, pifithrin- (55) does not
only exploit the p53 pathway but also heat shock and gluco-
corticoid receptor signalling, among others (56,57). By ma-
nipulating the p53 pathway in such a gentle manner, Nb139
creates a unique opportunity to investigate the combinato-
rial effects of, e.g. p53 binding proteins, post-translational
modifications and stress signals on the transcriptional pro-
gram. Since the p53 response is context-dependent, and we
only tested U2OS cells treated with etoposide, the applica-
tion of Nb139 in various backgrounds, with regard to use
of cell lines and stress-inducing treatments, will undoubt-
edly provide insight into the regulatory mechanics of the
transcription-dependent functions.
Additionally, Nb139 may be of interest in regard to the
transcription-independent functions of p53 as the DBD is
also an instrument of apoptotic regulation in the cytosol
(7,58,59). Mihara et al. first touched upon the subject of
transcription-independent functions of p53 (7). Since then,
this process has been well characterized (60). However, cer-
tain questions do remain, e.g. interaction of p53 with Bcl2
protein family members and the effect(s) of mutant p53 in
the cytosol. As such, Nb139 may prove to be an ideal crys-
tallization chaperone (61) to stabilize the weak p53-BAX
interaction, since it theoretically does not interfere with the
p53-protein-binding interface. This would thus allow to elu-
cidate the molecular details of this interaction.
Furthermore, both nanobodies can also be applied to
track the localization of cytosolic mutant p53 as it has not
been established whether mutations in p53 affect its cyto-
plasmic translocation (62). The application of nanobodies
as intracellular probes has already been demonstrated in nu-
merous cases (10,11,13,16,17,63). In addition, Nb139 can
be used as a stepping stone for the rational design of gain-
of-function inhibitors. As most common types of cancer-
associated p53 mutations abrogate p53’s tumor suppressive
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activity, it has also been established that some endow the
mutant protein with new activities, e.g. enhanced invasion
and anti-apoptotic activity, that actively contribute to var-
ious stages of tumor progression and increase resistance to
anticancer treatments (64). As such, mutant p53 is a valid
target for inactivation by prospective anticancer therapies.
In conclusion, Nb3 and Nb139 are novel research tools
that will permit an innovative approach to various branches
of the intricate field of p53.
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